TESTING REFERENCE

GENE PANEL PANEL DESCRIPTION
CYP2C9-VKORC1 The Cytochrome P450 2C9 (CYP2C9) is involved in the metabolism of 15% of clinically important medications including various Psychotropics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), and Hypoglycemics, among others. This enzyme is highly polymorphic and to date, 30 different variant alleles have been identified.

The CYP2C9 assay identifies some common variants that are associated variability in CY2C19enzyme activity, which has important pharmacological and toxicological implications for anticonvulsants and certain antidepressants. (VKORCl) enzyme Is primary responsible for the metabolism of a person’s vitamin K intake. The presence of variations in these genes can result in increased or decreased sensitivity to various medications.

CYP2C19 The Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of 10% of clinically important medications including various Psychotropics, Anti-convulsants and Proton Pump Inhibitors (PPis), among others.

This enzyme is highly polymorphic and more than 30 different variant alleles have been identified. The CYP2C19 assay identifies some common variants that are associated variability in CY2C19enzyme activity, which has important pharmacological and toxicological implications for antidepressants and some benzodiazepines.

CYP2D6 The Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 25% of clinically important medications including various Psychotropics, Analgesics, and Beta-blockers, among others. This enzyme is highly polymorphic and more than 100 different variant alleles have been identified.

The CYP2D6 assay identifies some common variants that are associated variability in CYP2D6enzyme activity, which has important pharmacological and toxicological implications for antidepressants and antipsychotics.

CYP3A4 The Cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3A5) account for 4D-80% of total CYP in human liver and intestine, respectively. Most importantly,CYP3A enzymes metabolize 50% of commonly used drugs including various Statins, Antibiotics/anti-virals, and Analgesics, among others.

CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and the contribution ofCYP3A5 in the overall metabolism is smaller than the one for CYP3A4. The overall CYP3Ametabolism status is expected to affect drug that have a narrow therapeutic index.

CYP3A5 The Cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3AS) account for 4D-80% of total CYP in human liver and intestine, respectively. Most importantly, CYP3A enzymes metabolize 5O% of commonly used drugs including various Statins, Antibiotics/anti-virals, and Analgesics, among others.

CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and the contribution ofCYP3A5 in the overall metabolism is smaller than the one for CYP3M. The overall CYP3A metabolism status is expected to affect drugs that have a narrow therapeutic index.

Factor 11-V MTHFR Factor II Prothrombin and Factor V Leiden gene variations are the two most common causes of inherited thrombophilia. Methylenetetrahydrofolate Reductase (MTHFR) gene mutations are strongly associated with hyperhomocysteinemia, which increases cardiovascular disease risk.

These markers provide important information when designing anti-coagulant therapy.

Back to Cancer Screening